𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antitumor activity of DAB389 IL-2 fusion toxin in mycosis fungoides

✍ Scribed by Mansoor N. Saleh; C.F. LeMaistre; Timothy M. Kuzel; Francine Foss; Leonidas C. Platanias; Gary Schwartz; Mark Ratain; Alain Rook; Cesar O. Freytes; Fiona Craig; James Reuben; Mitchell W. Sams; Jean C. Nichols

Book ID
117396462
Publisher
Elsevier Science
Year
1998
Tongue
English
Weight
166 KB
Volume
39
Category
Article
ISSN
1097-6787

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

DAB389IL2 diphtheria fusion toxin produc
DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma
✍ Duvic, Madeleine; Cather, Jennifer; Maize, John; Frankel, Arthur E. πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 61 KB

Four patients with late stage cutaneous T cell lymphoma (IB-IVA) who had failed at least two previous therapies were treated with DAB 389 IL2 at 9 or 18 Β΅g/kg as 15-min intravenous infusions daily for 5 days every 3 weeks for eight cycles. Mild vascular leak syndrome (VLS) with transient edema, hypo

Expression and activity of IL-17 in cuta
Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and sezary syndrome)
✍ Arnaud CirΓ©e; Laurence Michel; Sophie Camilleri-BrΓΆet; Francette Jean Louis; Mic πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 412 KB πŸ‘ 1 views

## Abstract Interleukin‐17 (IL‐17) is a proinflammatory cytokine mainly produced by activated CD4^+^ CD45RO T cells. In mice, we have demonstrated that, depending on the model, IL‐17 may act as a tumor growth‐promoting or ‐inhibiting factor. In order to address the relevance of these models in huma